WaferGen Biosystems Inc. (WGBS)

[difumetti]

Zacks Short Term Rating on WaferGen Bio-systems, Inc. (NASDAQ:WGBS)

WaferGen Bio-systems, Inc. (NASDAQ:WGBS) has received a hold rating for the short term, according to the latest rank of 3 from research firm, Zacks. The company received an average rating of 1 from 2 analysts. 2 have rated it as a strong buy.

WaferGen Bio-systems, Inc. (NASDAQ:WGBS): The mean estimate for the short term price target for WaferGen Bio-systems, Inc. (NASDAQ:WGBS) stands at $8.5 according to 2 Analysts. The higher price target estimate for the stock has been calculated at $11 while the lower price target estimate is at $6.

WaferGen Bio-systems, Inc. (NASDAQ:WGBS) witnessed a decline in the market cap on Tuesday as its shares dropped 2.75% or 0.03 points. After the session commenced at $1.11, the stock reached the higher end at $1.11 while it hit a low of $1. With the volume soaring to 1,486,580 shares, the last trade was called at $1.06. The company has a 52-week high of $5.89. The company has a market cap of $6 million and there are 5,706,653 shares in outstanding. The 52-week low of the share price is $0.97.

The company shares have dropped -67.85% from its 1 Year high price. On Feb 25, 2015, the shares registered one year high at $5.89 and the one year low was seen on Sep 4, 2015. The 50-Day Moving Average price is $1.57 and the 200 Day Moving Average price is recorded at $2.80.

WaferGen Bio-systems, Inc. (WBSI) is engaged in the development, manufacture and marketing of laboratory analytical instruments for cell biology, and later started the development of analytical instrumentation for gene expression and genotyping research for the life sciences and pharmaceutical drug discovery industries. WBSI is primarily focused on developing a gene expression and genotyping product, the WaferGen SmartChip System. The Company has first generation SmartChip 5K System, which is a polymerase chain reaction (real-time PCR)2 tool to enable scientists to study thousands of genes simultaneously based on gene specific pathways, potentially to discovery of clinically relevant disease signatures. It also provides in-house gene-expression profiling for sales demonstrations and collaborations using the SmartChip System. In January 2014, the Company announced that it has completed the acquisition of the NGS library preparation business from IntegenX Inc.

http://www.moneyflowindex.org/zacks-short-term-rating-on-wafergen-bio-systems-inc-nasdaqwgbs/3170790/